Kiniksa Pharmaceuticals Ltd (KNSA)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $7.57B
Last updated: Nov 17, 2026 at 11:06 AM ET
Kiniksa Pharmaceuticals Ltd (KNSA) Government Contracts
Federal agencies obligated $328,283 to Kiniksa Pharmaceuticals over the 12 months through Jul 31, 2026. That is less than 1% of its revenue. Department of Veterans Affairs was its only awarding agency.
Federal Obligations
Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated.
- Obligations
- $328,283
- Obligations to revenue
- 0.0%
| Prior 12 months | $355,009 |
|---|---|
| Contracts with activity | 6 |
| New contracts | 5 |
| Top agency | Department of Veterans Affairs |
| Top agency share | 100.0% |
|---|---|
| Agencies | 1 |
| Average remaining term | 4.3 months |
12 months through Jul 31, 2026
Largest New Awards
The 5 largest new awards total $354,484, and the largest makes up 62.1% of that.
| Award ID | Agency | Amount | Start | End | Description |
|---|---|---|---|---|---|
| 36C26026F0076 | Department of Veterans Affairs | $220,229 | Dec 15, 2025 | Dec 14, 2026 | BULK - ARCALYST 220MG VIL |
| 36C24526N0294 | Department of Veterans Affairs | $34,023 | Jan 31, 2026 | Feb 4, 2026 | ARCALYST 200 MG |
| 36C24526N0418 | Department of Veterans Affairs | $34,023 | Mar 18, 2026 | Mar 24, 2026 | ARCALYST 200 MG |
| 36C24526N0595 | Department of Veterans Affairs | $34,023 | May 21, 2026 | May 27, 2026 | ARCALYST 220 MG |
| 36C24526N0196 | Department of Veterans Affairs | $32,187 | Dec 22, 2025 | Dec 30, 2025 | ARCALYST 200 MG |
Monthly Obligations
The latest complete month, Apr 2026, had no net obligations. The largest month in the table was Oct 2025, at $209,215.
| Month | Obligations |
|---|---|
| Jul 2026 | $0 |
| Jun 2026 | $0 |
| May 2026 | $34,023 |
| Apr 2026 | $0 |
| Mar 2026 | $34,023 |
| Feb 2026 | $11,015 |
| Jan 2026 | $34,023 |
| Dec 2025 | $32,187 |
| Nov 2025 | -$26,201 |
| Oct 2025 | $209,215 |
| Sep 2025 | $0 |
| Aug 2025 | $0 |
| Month | Obligations |
|---|---|
| Jul 2025 | -$48,280 |
| Jun 2025 | $0 |
| May 2025 | $0 |
| Apr 2025 | $191 |
| Mar 2025 | $5,533 |
| Feb 2025 | $0 |
| Jan 2025 | $190,832 |
| Dec 2024 | $206,734 |
| Nov 2024 | $0 |
| Oct 2024 | $0 |
| Sep 2024 | $0 |
| Aug 2024 | $0 |
Net obligations recorded each month, newest first. Agencies report contract actions with a delay (the Defense Department about 90 days), so the latest months, May to Jul 2026, are still incomplete and the 12-month total usually rises as agencies report the rest.
Frequently Asked Questions About KNSA
How much does Kiniksa Pharmaceuticals receive in federal contracts?
Kiniksa Pharmaceuticals had $328,283 in federal contract obligations over the 12 months through Jul 31, 2026, compared with $355,009 in the 12 months before. Obligations are contract bookings by the awarding agency, not recognized revenue.
What are Kiniksa Pharmaceuticals' largest government contracts?
The largest new awards over the 12 months through Jul 31, 2026 were 36C26026F0076, Department of Veterans Affairs, $220,229, started Dec 15, 2025; 36C24526N0294, Department of Veterans Affairs, $34,023, started Jan 31, 2026; 36C24526N0418, Department of Veterans Affairs, $34,023, started Mar 18, 2026.
Which agencies award Kiniksa Pharmaceuticals contracts?
Department of Veterans Affairs was its only awarding agency over the 12 months through Jul 31, 2026.
What new federal contracts did Kiniksa Pharmaceuticals win in the 12 months through Jul 31, 2026?
Kiniksa Pharmaceuticals won 5 new federal contracts in the 12 months through Jul 31, 2026. The largest was 36C26026F0076, Department of Veterans Affairs, $220,229, started Dec 15, 2025.
How do Kiniksa Pharmaceuticals' federal obligations compare with its revenue?
Federal contract obligations were $328,283 over the 12 months through Jul 31, 2026, equivalent to less than 1% of Kiniksa Pharmaceuticals' revenue. Obligations are amounts the government committed to contracts in the period, not the share of Kiniksa Pharmaceuticals' revenue that comes from the government.
KNSA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts